BCC
TGTX icon

Bridge City Capital’s TG Therapeutics TGTX Stock Holding History

Bridge City Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.88M Sell
88,896
-1,738
-2% -$71.1K 1.11% 27
2026
Q1 		$3.01M Buy
+90,634
New +$2.7M 0.83% 45

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Bridge City Capital's TGTX Position: Q2 2026 in Review

Bridge City Capital reduced its TG Therapeutics (TGTX) stake by 1.9% in Q2 2026, selling an estimated $71.1K and leaving 88,896 shares worth $4.88M. The position accounts for 1.11% of the portfolio, ranked #27.

Bridge City Capital first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Bridge City Capital held 88,896 shares of TG Therapeutics worth $4.88M as of Q2 2026.
  • Bridge City Capital sold 1,738 TG Therapeutics shares in Q2 2026, an estimated $71.1K.
  • TG Therapeutics made up 1.11% of Bridge City Capital's portfolio in Q2 2026, its #27 holding.
  • Bridge City Capital first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Bridge City Capital's 13F filing for Q2 2026, filed 11 Aug 2026.